Physician profile
Colleen Ralph
NPI 1760913792
$1,159.19
in general payments reported to CMS, 2019-2025
21 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.46 · 2022: $51.33 · 2023: $368 · 2024: $530 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $220.79 | 2023-2025 | Pomalyst, Reblozyl |
| Genentech, INC. | $145.53 | 2024 | Avastin, Phesgo, Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $116.40 | 2024-2025 | Opdualag |
| Aimmune Therapeutics, INC. | $109.62 | 2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $101.85 | 2023-2024 | |
| Seagen INC. | $49.23 | 2023 | Tivdak, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $48.53 | 2021-2022 | |
| Genentech USA, INC. | $48.30 | 2023 | Tecentriq |
| Janssen Pharmaceuticals, INC | $40.95 | 2023-2024 | Xarelto |
| Aveo Pharmaceuticals, INC. | $33.03 | 2024 | |
| Mirati Therapeutics, INC. | $29.72 | 2023 | Krazati |
| Amgen INC. | $29.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.75 | 2024 | Ultomiris |
| Exelixis INC. | $26.17 | 2023 | Cabometyx |
| Blueprint Medicines Corporation | $22.65 | 2024 | Ayvakit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.61 | 2024 | |
| Lilly USA, LLC | $21.02 | 2024 | Retevmo, Jaypirca, Verzenio |
| Springworks Therapeutics, INC. | $18.87 | 2024 | Ogsiveo |
| Genmab U.S., INC. | $17.28 | 2024 | Epkinly |
| Merck Sharp & Dohme LLC | $16.34 | 2024 | Keytruda, Lynparza |
| Azurity Pharmaceuticals, INC. | $15.29 | 2024 | Vivimusta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Ralph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.